EraCal Therapeutics

1. Executive Summary (Confidence: High)

EraCal Therapeutics AG, incorporated in 2018, is a high-trajectory biotech firm disrupting the metabolic disease landscape. The firm’s "Front-Running Program," Era-379, was outlicensed to Novo Nordisk in January 2024 for €235 million plus royalties, a deal that cements EraCal’s status as a leader in "next-generation anti-obesity pharmacotherapy". EraCal’s competitive edge is its peer-reviewed zebrafish drug discovery platform, which enables high-throughput, whole-organism phenotypic screening of human-relevant molecules. Beyond its pharma partnership with Novo Nordisk, the company is also collaborating with Nestlé Health Science to develop novel nutraceuticals, positioning itself as a "multi-vertical" innovator in metabolic health.